Scilex Holding (SCLXW) Change in Accured Expenses (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Change in Accured Expenses of -$7.8 million in Q1 2026, down 2563.82% quarter-over-quarter from -$293000.0 in Q4 2025, and down 1028.06% on a YoY basis from $841000.0 in Q1 2025.
Scilex Holding (SCLXW) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Scilex Holding's Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$7.8 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 1028.06% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at $6.0 million (up 170.51% YoY), while the FY2025 annual figure was $14.6 million, up 278.78% from the prior year.
- Change in Accured Expenses was -$7.8 million for Q1 2026 at Scilex Holding, down from -$293000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $14.3 million in Q3 2025 to a low of -$10.6 million in Q4 2024.
- Historically, Change in Accured Expenses has averaged $32176.5 across 5 years, with a median of -$126000.0 in 2022.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 19597.95% in 2022, then soared 29625.0% in 2023.
- A 5-year view of Change in Accured Expenses shows it stood at $981000.0 in 2022, then slumped by 427.73% to -$3.2 million in 2023, then slumped by 230.64% to -$10.6 million in 2024, then surged by 97.24% to -$293000.0 in 2025, then plunged by 2563.82% to -$7.8 million in 2026.
- The last three Change in Accured Expenses figures came in at -$7.8 million (Q1 2026), -$293000.0 (Q4 2025), and $14.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -629.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -1.59 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -75.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -702.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -3.50 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -7.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.81 Mn |
| Mar 31, 2026 | -7.81 Mn |
| Dec 31, 2025 | -293,000.00 |
| Dec 31, 2025 | -293,000.00 |
| Sep 30, 2025 | 14.30 Mn |
| Sep 30, 2025 | 14.30 Mn |
| Jun 30, 2025 | -242,000.00 |
| Jun 30, 2025 | -242,000.00 |
| Mar 31, 2025 | 841,000.00 |
| Mar 31, 2025 | 841,000.00 |
| Dec 31, 2024 | -10.63 Mn |
| Dec 31, 2024 | -10.63 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | -650,000.00 |
| Jun 30, 2024 | -650,000.00 |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | -3.22 Mn |
| Dec 31, 2023 | -3.22 Mn |